PDF herunterladen
Psychiatr Prax 2014; 41(08): 407-409
DOI: 10.1055/s-0034-1370253
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Sinkende Neuerkrankungsraten für Demenzen? – Implikationen für eine public-health-orientierte Prävention

Decreasing Dementia Incidence Rates? – Implications for Public Health and Prevention
Steffi G. Riedel-Heller
Institut für Sozialmedizin, Arbeitsmedizin und Public Health (ISAP), Universität Leipzig
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. August 2014 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Neue Befunde

Demenzerkrankungen zählen zu den häufigsten und folgenschwersten psychischen Störungen im Alter, für den Einzelnen, aber auch für die Solidargemeinschaft. Für Deutschland liegen die jährlichen Kosten aus gesamtgesellschaftlicher Perspektive (AgeCoDe-Studie) für leichte Demenzen bei 15 000 Euro, für mittelschwere Demenzen bei 32 000 Euro und bei schweren demenziellen Erkrankungen bei 42 000 Euro [1].

Aktuelle Hochrechnungen gehen davon aus, dass die Zahl Demenzkranker in Europa bis 2050 auf 14 Millionen steigen wird [2].

 

  • Literatur

  • 1 Leicht H, Heinrich S, Heider D et al. Net costs of dementia by disease stage. Acta Psychiatr Scand 2011; 124: 384-395
    CrossrefPubMedGoogle Scholar
  • 2 Mura T, Dartigues JF, Berr C. How many dementia cases in France and Europe? Alternative projections and scenarios 2010–2050. Eur J Neurol 2010; 17: 252-259
    CrossrefPubMedGoogle Scholar
  • 3 Norton S, Matthews FE, Brayne C. A commentary on studies presenting projections of the future prevalence of dementia. BMC Public Health 2013; 13: 1
    CrossrefPubMedGoogle Scholar
  • 4 Matthews FE, Arthur A, Barnes LE et al. Medical Research Council Cognitive Function and Ageing Collaboration. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013; 382: 1405-1412
    CrossrefPubMedGoogle Scholar
  • 5 Christensen K, Thinggaard M, Oksuzyan A et al. Physical and cognitive functioning of people older than 90 years: a comparison of two Danish cohorts born 10 years apart. Lancet 2013; 382: 1507-1513
    CrossrefPubMedGoogle Scholar
  • 6 Qiu C, von Strauss E, Bäckman L et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013; 80: 1888-1894
    CrossrefPubMedGoogle Scholar
  • 7 Mangialasche F, Kivipelto M, Solomon A et al. Dementia prevention: current epidemiological evidence and future perspective. Alzheimers Res Ther 2012; 4: 6
    CrossrefPubMedGoogle Scholar
  • 8 DiMarco LY, Marzo A, Muñoz-Ruiz M et al. Modifiable Lifestyle Factors in Dementia: A Systematic Review of Longitudinal Observational Cohort Studies. J Alzheimers Dis DOI: 10.3233/JAD-132225.
    PubMedGoogle Scholar
  • 9 Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer’s disease?. Mol Psychiatry 2013; 18: 864-874
    CrossrefPubMedGoogle Scholar
  • 10 Luck T, Riedel-Heller SG, Luppa M et al. Apolipoprotein E epsilon 4 genotype and a physically active lifestyle in late life: analysis of gene-environment interaction for the risk of dementia and Alzheimer’s disease dementia. Psychol Med 2013; 44: 1319-1329
    PubMedGoogle Scholar
  • 11 Erickson KI, Voss MW, Prakash RS et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A 2011; 108: 3017-3022
    CrossrefPubMedGoogle Scholar
  • 12 Erickson KI, Weinstein AM, Lopez OL. Physical activity, brain plasticity, and Alzheimer’s disease. Arch Med Res 2012; 43: 615-621
    CrossrefPubMedGoogle Scholar
  • 13 Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280-292
    CrossrefPubMedGoogle Scholar
  • 14 Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol 2007; 6: 734-746
    CrossrefPubMedGoogle Scholar
  • 15 Jack Jr CR, Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 257-262
    CrossrefPubMedGoogle Scholar
  • 16 Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270-279
    CrossrefPubMedGoogle Scholar
  • 17 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition (DSM-V). Arlington: APA; 2013
    Google Scholar
  • 18 Solomon A, Mangialasche F, Richard E et al. Advances in the prevention of Alzheimer’s disease and dementia. J Intern Med 2014; 275: 229-250
    CrossrefPubMedGoogle Scholar
  • 19 Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 2011; 10: 819-828
    CrossrefPubMedGoogle Scholar
  • 20 Reither EN, Olshansky SJ, Yang Y. New forecasting methodology indicates more disease and earlier mortality ahead for today’s younger Americans. Health Aff (Millwood) 2011; 30: 1562-1568
    CrossrefPubMedGoogle Scholar
  • 21 Schneider LS, Mangialasche F, Andreasen N et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 2014; 275: 251-283
    CrossrefPubMedGoogle Scholar